Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy is affecting perioperative treatment in early-stage non–small cell lung cancer.
Dissecting Perioperative Immunotherapy Approaches in Early-Stage NSCLC
Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated data from CheckMate-77T of perioperative nivolumab in resectable NSCLC.
Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.
Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss updated findings for neoadjuvant nivolumab plus chemotherapy in resectable NSCLC.
Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss factors that affect adjuvant treatment decisions in early non–small cell lung cancer.
Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy could continue to reshape early NSCLC management.
Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss ongoing research in early-stage non–small cell lung cancer.
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
5